These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 11695314)

  • 21. Mutations in the interferon sensitivity-determining region of hepatitis C virus genotype 2a correlate with response to pegylated-interferon-alpha 2a monotherapy.
    Hayashi K; Katano Y; Honda T; Ishigami M; Itoh A; Hirooka Y; Nakano I; Urano F; Yoshioka K; Toyoda H; Kumada T; Goto H
    J Med Virol; 2009 Mar; 81(3):459-66. PubMed ID: 19152412
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predicting treatment outcome following 24 weeks peginterferon alpha-2a/ribavirin therapy in patients infected with HCV genotype 1: utility of HCV-RNA at day 0, day 22, day 29, and week 6.
    Lukasiewicz E; Hellstrand K; Westin J; Ferrari C; Neumann AU; Pawlotsky JM; Schalm SW; Zeuzem S; Veldt BJ; Hansen BE; Verhey-Hart E; Lagging M
    Hepatology; 2007 Jan; 45(1):258-9. PubMed ID: 17187414
    [No Abstract]   [Full Text] [Related]  

  • 23. [IL-28B polymorphism and hepatitis C: impact on viral clearance--prolonged, spontaneous and after treatment with antiviral drugs].
    Halfon P; Cacoub P
    Rev Med Interne; 2011 May; 32(5):271-4. PubMed ID: 21126807
    [No Abstract]   [Full Text] [Related]  

  • 24. Sexually transmitted reinfection with a new hepatitis C genotype during pegylated interferon and ribavirin therapy.
    den Hollander JG; Rijnders BJ; van Doornum GJ; van der Ende ME
    AIDS; 2005 Mar; 19(6):639-40. PubMed ID: 15802989
    [No Abstract]   [Full Text] [Related]  

  • 25. Successful pegylated interferon alpha2a monotherapy for hepatitis C virus infection in a transplanted patient who relapsed after the preceding course.
    Ichikawa T; Taura N; Miyaaki H; Matsuzaki M; Eguchi S; Takatsuki M; Kanematsu T; Nakao K
    Transpl Infect Dis; 2011 Aug; 13(4):438-40. PubMed ID: 21309967
    [No Abstract]   [Full Text] [Related]  

  • 26. Peginterferon alfa-2b vs. peginterferon alfa-2a in the treatment of hepatitis C, is there any difference?
    Sierra F
    J Hepatol; 2007 Feb; 46(2):349; author reply 349-50. PubMed ID: 17161495
    [No Abstract]   [Full Text] [Related]  

  • 27. Peginterferon alfa-2a (40KD): a potent long-acting form of interferon alfa-2a for the treatment of hepatitis C.
    Modi MW; Lamb MW; Shiomi M
    Adv Exp Med Biol; 2003; 519():59-67. PubMed ID: 12675208
    [No Abstract]   [Full Text] [Related]  

  • 28. [Is the type of pegylated interferon important for response to treatment in patients with chronic hepatitis C infection?].
    Buti M
    Enferm Infecc Microbiol Clin; 2008 Mar; 26(3):125-6. PubMed ID: 18358209
    [No Abstract]   [Full Text] [Related]  

  • 29. Twelve-week posttreatment follow-up predicts a sustained virological response to pegylated interferon and ribavirin therapy.
    Aghemo A; Rumi MG; De Nicola S; Colombo M
    Hepatology; 2010 Sep; 52(3):1170-1. PubMed ID: 20812363
    [No Abstract]   [Full Text] [Related]  

  • 30. Successful Hepatitis C Eradication With Preservation of Renal Function in a Liver/kidney Transplant Recipient Using Pegylated Interferon and Ribavirin.
    Mukherjee S; Ariyarantha K
    Transplantation; 2007 Nov; 84(10):1374-5. PubMed ID: 18049127
    [No Abstract]   [Full Text] [Related]  

  • 31. Pegylated interferon-alpha2a and ribavirin in HIV-hepatitis C coinfected patients.
    Expert Rev Anti Infect Ther; 2004 Jun; 2(3):341-2. PubMed ID: 15490503
    [No Abstract]   [Full Text] [Related]  

  • 32. Viral hepatitis C.
    Poynard T; Yuen MF; Ratziu V; Lai CL
    Lancet; 2003 Dec; 362(9401):2095-100. PubMed ID: 14697814
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of acute hepatitis C-how to explain the differences?
    Wedemeyer H; Cornberg M; Wiegand J; Jäckel E; Manns MP
    Gastroenterology; 2006 Aug; 131(2):682-3; author reply 683-4. PubMed ID: 16890627
    [No Abstract]   [Full Text] [Related]  

  • 34. Adverse drug effects and pegylation.
    Wooten JM
    South Med J; 2011 Feb; 104(2):83-4. PubMed ID: 21206333
    [No Abstract]   [Full Text] [Related]  

  • 35. Predictors of response of U.S. veterans to treatment for the hepatitis C virus.
    Riley TR
    Hepatology; 2008 Jan; 47(1):356; author reply 356-7. PubMed ID: 18161713
    [No Abstract]   [Full Text] [Related]  

  • 36. Hepatitis C virus infection: a current review.
    Senecal DL; Morelli J
    JAAPA; 2007 Oct; 20(10):21-5. PubMed ID: 18019325
    [No Abstract]   [Full Text] [Related]  

  • 37. Acute viral hepatitis C should be treated.
    Dhiman RK; Chawla Y
    Indian J Gastroenterol; 2005; 24(2):68-71. PubMed ID: 15879654
    [No Abstract]   [Full Text] [Related]  

  • 38. Error in calculation of indirect analyses.
    Chou R; Chan BK
    J Viral Hepat; 2009 May; 16(5):376. PubMed ID: 19341421
    [No Abstract]   [Full Text] [Related]  

  • 39. Care of patients with hepatitis C and HIV co-infection.
    Soriano V; Puoti M; Sulkowski M; Mauss S; Cacoub P; Cargnel A; Dieterich D; Hatzakis A; Rockstroh J
    AIDS; 2004 Jan; 18(1):1-12. PubMed ID: 15090824
    [No Abstract]   [Full Text] [Related]  

  • 40. Catatonia associated with pegylated interferon-α 2b and ribavirin for hepatitis C.
    Quinn D; Kuchler E; Deming P; Arora S
    Psychosomatics; 2012; 53(4):400-1. PubMed ID: 22748752
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.